dc.creatorMeneguin, Silmara
dc.creatorCesar, Luiz Antônio Machado
dc.date.accessioned2013-11-04T13:00:44Z
dc.date.accessioned2018-07-04T16:39:12Z
dc.date.available2013-11-04T13:00:44Z
dc.date.available2018-07-04T16:39:12Z
dc.date.created2013-11-04T13:00:44Z
dc.date.issued2012
dc.identifierClinics,v.67,n.6,p.603-608,2012
dc.identifier1807-5932
dc.identifierhttp://www.producao.usp.br/handle/BDPI/40394
dc.identifier10.6061/clinics/2012(06)10
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322012000600010&lng=en&nrm=iso&tlng=en
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_abstract&pid=S1807-59322012000600010&lng=en&nrm=iso&tlng=en
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_pdf&pid=S1807-59322012000600010&lng=en&nrm=iso&tlng=en
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1638517
dc.description.abstractOBJECTIVE: The participation of humans in clinical cardiology trials remains essential, but little is known regarding participant perceptions of such studies. We examined the factors that motivated participation in such studies, as well as those that led to participant frustration. METHODS: Patients who had participated in hypertension and coronary arterial disease (phases II, III, and IV) clinical trials were invited to answer a questionnaire. They were divided into two groups: Group I, which included participants in placebo-controlled clinical trials after randomization, and Group II, which included participants in clinical trials in which the tested treatment was compared to another drug after randomization and in which a placebo was used in the washout period. RESULTS: Eighty patients (47 patients in Group I and 33 patients in Group II) with different socio-demographic characteristics were interviewed. Approximately 60% of the patients were motivated to participate in the trial with the expectation of personal benefit. Nine participants (11.2%) expressed the desire to withdraw, which was due to their perception of risk during the testing in the clinical trial (Group I) and to the necessity of repeated returns to the institution (Group II). However, the patients did not withdraw due to fear of termination of hospital treatment. CONCLUSIONS: Although this study had a small patient sample, the possibility of receiving a benefit from the new tested treatment was consistently reported as a motivation to participate in the trials.
dc.languageeng
dc.publisherFaculdade de Medicina / USP
dc.relationClinics
dc.rightsopenAccess
dc.subjectMotivation
dc.subjectClinical trials
dc.subjectFrustration
dc.subjectCardiology
dc.titleMotivation and frustration in cardiology trial participation: the patient perspective
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución